34 results about "Pharmacotherapy" patented technology

The present application relates to the field of medicinal chemistry and pharmacotherapy, and in particular to a class of bazedoxifene and its preparation method and application. The bazedoxifene derivative is used for gp130 small molecule inhibitor, the compound is a compound shown in formula (I), or a pharmaceutically acceptable salt or ester thereof, and relates to the application of tumor-related activity and the like, in particular the application in preparing drugs for preventing and / or treating diseases related to tumors, especially colorectal cancer.

FIELD: neurology; psychiatry.SUBSTANCE: used as a non-pharmacological therapy for autism spectrum disorders in children. The method includes a set of procedures: interval hypoxic-hyperoxic training (HHT), hyperbaric oxygenation and ozone therapy. HHT consists of alternating inhalations of a hypoxic mixture with an oxygen content of 9 to 16 vol.% and a hyperoxic mixture with an oxygen content of 32 to 40 vol.% for a total duration of 45-50 minutes under the control of cardiovascular system parameters. Hyperbaric oxygenation is performed in a pressure chamber under a pressure of 1.3 atmospheres of 100% oxygen mixture, flow of 10 liters per minute, for 45 minutes using a mask. Ozone therapy is performed by rectal insufflation with an ozone-oxygen mixture with an ozone concentration of 85 μg / ml in a volume of 20–30 ml or by intravenous administration of a physiological solution enriched with ozone with an ozone concentration of 85 μg / ml at a rate of 200 ml per 100 ml of physiological solution. The procedures are carried out daily for 12 days.EFFECT: method is effective and has a positive impact on the patient’s condition.1 cl, 1 dwg, 3 ex

Methods and compounds to therapeutically treat a molecular target to counteract circuit adaptations of long-term opioid use that are associated with a functional disability and negative affect in both CBP−O (chronic back pain managed without opioids) and CBP+O (chronic back pain managed with opioids).

Disclosed are methods to treat patients with AFib by monitoring their heart rhythm to determine the presence and / or the number of episodes of long duration AFib, and optionally the extent of AFib burden. Patients who meet threshold requirements are qualified for the treatment of AFib with a dosage of budiodarone. Patient monitoring is continued in order confirm that the patient is and remains responsive to budiodarone therapy including dose adjusting the patient to achieve such therapy. Subsequently, monitoring is continued to confirm that the patient remains responsive. These methods allow for treatment of the AFib and, correspondingly, reduce or delay the risk of stroke and / or congestive heart failure in the treated patient.

The invention discloses pine-soot ink moxibustion as well as a preparation method and a use method thereof, and relates to the technical field of traditional Chinese medicine moxibustion therapy. Comprising the following raw materials: pine-soot ink, tourmaline powder, radix aconiti preparata, semen strychni preparata, sanguisorba officinalis, rhizoma corydalis, pseudo-ginseng, angelica sinensis, safflower carthamus, ligusticum wallichii, radix saposhnikoviae, gastrodia elata, frankincense, earthworm, herba epimedii, dogwood, lucid ganoderma, astragalus membranaceus, gynostemma pentaphyllum, artificial musk, wintergreen oil, borneol and beautifying wax. According to the pine-soot ink moxibustion and the preparation method and the use method thereof, the pine-soot ink is used as a substrate, the tourmaline powder is compounded, and a raw material system of multiple traditional Chinese medicines is selected, so that the product not only has the hot compress and pharmacodynamic permeation functions of the traditional Chinese medicines, but also has the adsorption characteristic of the pine-soot ink and the physical effects of negative ion release and far infrared effect generation of tourmaline; multiple synergy of a drug therapy and a physical therapy is realized, so that better health-care effects of relaxing tendons and activating collaterals, dispelling cold and removing dampness and relieving bone and joint pain are achieved.

A method for developing novel drug therapies utilizing properties of existing drug therapies, the method comprising the steps of: developing a novel therapeutic mathematical model of a target biological network and synthesizing a drug therapy based on the novel therapeutic mathematical model. The novel therapeutic mathematical model is capable of generating novel therapeutic time-course progressions, which include time-course progression features found in existing therapeutic time-course progressions of existing therapeutic mathematical models of the target biological network. The time-course progression features can be correlated with the outcomes of the target biological network. Each new therapeutic intervention constant can be used to synthesize a drug regimen, and these drug regimens collectively constitute the novel drug therapy.

A system for training medical providers in obesity management and obesity-related comorbidities includes a user device presenting a conversational interface to a medical provider, an application server managing user sessions, a database server storing user data including course completion records and clinical performance audits, and a learning management system server delivering educational modules based on established competencies. An artificial intelligence server processes queries from the medical provider and provides personalized medical advice using a large language model trained on obesity-related medical content including obesity physiology, pharmacotherapy, and patient management. The artificial intelligence server receives outcome information related to patient health metrics following the personalized medical advice and retrains the large language model based on the outcome information. A performance audit system monitors clinical documentation, prescribing patterns, and patient outcomes of the medical provider to ensure ongoing compliance and performance improvements.

The present invention relates to the use of the GLP-1 receptor agonist semeglutide in a pharmaceutical therapy for the treatment of ejection fraction retention heart failure (HFpEF).

Pharmaceutical formulations comprising buromantan or analogs of buromantan are disclosed, as well as methods of using the formulations for pharmaceutical therapy to reduce withdrawal syndrome and prevent relapse in the treatment of stimulant use disorders, to quit patients from drugs having a predisposition to abuse or addiction, or to promote regression learning in the treatment of mental disorders.

The system according to this embodiment aims to integrate patient data and enable healthcare professionals to make quick and accurate diagnoses and develop treatment plans. [Solution] The system according to the embodiment comprises a data collection unit, an analysis unit, a data provision unit, and a prediction unit. The data collection unit collects patient data. The analysis unit analyzes the data collected by the data collection unit. The data provision unit provides the analysis results obtained by the analysis unit to healthcare professionals. The prediction unit predicts the effectiveness of treatment plans and drug therapy based on the analysis results provided by the data provision unit.

The present invention relates to a system and method for managing neurological and psychological disorders, with a specific focus on Obsessive-Compulsive Disorder (OCD). The invention integrates pharmacotherapy, Deep Transcranial Magnetic Stimulation (Deep TMS), and Exposure and Response Prevention (ERP) therapy into a unified framework that addresses the chemical, neurological, and behavioural dimensions of OCD. The system utilizes advanced data analysis and machine learning algorithms to dynamically customize interventions based on patient-specific profiles, ensuring optimal therapeutic efficacy and reduced side effects. The System includes real-time data-driven adjustments, high-intensity engagement protocols, remote monitoring for long-term management, and scalable group therapy capabilities. The system also incorporates advanced neuromodulation technologies and compressed ERP techniques to accelerate behavioural restructuring and neural circuit modulation. By leveraging the synergy between these modalities, the invention provides a holistic and versatile solution for improving patient outcomes, ensuring sustained symptom relief and enhanced quality of life.

The invention belongs to the technical field of model training, and provides a post-disaster psychological intervention model training method, which comprises the following steps: S1, acquiring sample medical record data, and extracting triple content from the sample medical record data; s2, determining a scene category according to the patient chief complaint content, and distributing a scene label and a scene knowledge base for the sample medical record data; s3, according to the scene category combination with the maximum word frequency, obtaining a diagnosis result and a disease severity degree score; s4, verifying the logic consistency of the diagnosis result obtained in the step S3 and the clinical diagnosis extracted in the step S1, and obtaining a logic deviation degree; if the logic deviation degree and the disease severity are smaller than or equal to the threshold value, executing S5; otherwise, returning to S3; and S5, based on the diagnosis result, generating an integrated treatment scheme of a drug therapy and a psychotherapy. The method effectively solves the problem that the number of professional psychologists is limited, and large-scale post-disaster psychological assistance requirements cannot be met, psychological intervention resources can break through the limitation of time, geography and human resources, and efficient distribution is achieved.

Compositions and methods are provided to determine occupancy level of opioid receptors in a subject. The disclosed methods may be performed non-invasively in the inner ear of the subject, and may be performed at a point-of-care location to provide guidance to a practitioner on tapering on pharmacotherapy or on a patient's risk of relapse for substance abuse.

The application discloses an indoline compound and a preparation method and application thereof, and belongs to the fields of medicinal chemistry and pharmacotherapy. The compound shown in the formula I, isomers or pharmaceutically acceptable salts thereof have good anti-HBV activity, can effectively inhibit the replication of HBV DNA, can be applied to the preparation of anti-HBV drugs, and have excellent potential application prospect.

Disclosed are pharmaceutical preparations comprising bromantane or an analogue of bromantane, and methods of using said preparations for pharmacotherapy to alleviate withdrawal syndrome and prevent relapse in the treatment of stimulant use disorder, to transition patients off medications that have abuse or addiction liabilities, or to facilitate extinction learning in the treatment of mental disorders.

Disclosed are methods to treat patients with AFib by monitoring their heart rhythm to determine the presence and / or the number of episodes of long duration AFib, and optionally the extent of AFib burden. Patients who meet threshold requirements are qualified for the treatment of AFib with a dosage of budiodarone. Patient monitoring is continued in order confirm that the patient is and remains responsive to budiodarone therapy including dose adjusting the patient to achieve such therapy. Subsequently, monitoring is continued to confirm that the patient remains responsive. These methods allow for treatment of the AFib and, correspondingly, reduce or delay the risk of stroke and / or congestive heart failure in the treated patient.

The invention relates to the technical field of medicinal chemistry and pharmacotherapeutics, and mainly relates to a carborane-containing isoflavone derivative as well as a preparation method and application thereof. The carborane-containing isoflavone derivative provided by the invention is a compound as shown in a formula (I) or pharmaceutically acceptable salt thereof, and also provides a preparation method thereof, the compound shows antitumor activity in related cancer cell lines, overcomes the defect that the active action site and mechanism of the isoflavone compound are not clear, and has a good application prospect. The BNCT nano-material has good targeting property, can realize double functions of BNCT precise positioning treatment and tumor growth and migration inhibition, and has very high clinical application value.

The invention relates to a profiled sheet material which has a resorbable porous collagen sponge in which resorbable nanoparticles or microparticles or combinations thereof are dispersed, wherein the nanoparticles or microparticles have at least two different release profiles for the controlled and / or delayed release of pharmaceutical active ingredients. The invention further relates to a method for producing the sheet material and to the use thereof in a method for treating wounds or in a method for local pharmacotherapy.

The invention relates generally to a method of treatment for a human genetic disease, such as diseases characterized by unbalanced nucleotide pools, e.g., mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency, using gene therapy. The gene therapy may involve administration of one or more constructs, such as a viral vector, containing a nucleic acid encoding a functional protein. The functional protein may correspond to a nuclear gene. For treatment of TK2 deficiency, the gene therapy may involve administration of one or more constructs, such as a viral vector, containing a nucleic acid encoding a functional TK2 enzyme. The treatment may also involve the administration of pharmacological therapy in conjunction with the gene therapy. The treatment protocols of the disclosure, such as those involving gene therapy alone or in combination with pharmacological therapy, can be used to treat, prevent, and / or cure various other disorders of unbalanced nucleoside pools, especially those found in mitochondrial DNA depletion syndrome.

To provide compounds for treating various conditions treated by activation of serotonin receptors, such as psychiatric diseases and other neurological diseases, disorders, and conditions, in the fields of psychiatry, neurobiology, and pharmacotherapy.SOLUTION: To provide a psilocin derivative of formula (I), a process for preparing the same, a composition containing the same, and use thereof in activating a serotonin receptor in a cell.SELECTED DRAWING: Figure 1

The present application relates to the field of medicinal chemistry and pharmacotherapy, in particular to a phenylpiperazine compound or a pharmaceutically acceptable salt thereof, a preparation method and use thereof in the preparation of analgesic drugs or drugs for treating pain, wherein the phenylpiperazine compound or the pharmaceutically acceptable salt thereof has the following structure: the phenylpiperazine compound has obvious inhibitory activity on TRPV1, can obviously inhibit the pain response, and has no side effect of body temperature rise.

The embodiment of the application relates to a kind of multi-source data fusion AI health state comprehensive evaluation method, comprising: collecting and AD disease condition assessment and management related multidimensional data;Multi-dimensional data are aligned in time and space, cleaning and standardization processing, and from it extract and AD disease evolution related time sequence characteristics, behavior pattern characteristics and clinical text features, and form multi-source fusion feature vector by fusion;Multi-source fusion feature vector is input into the preset deep learning evaluation model, and the quantitative evaluation result of current patient is obtained;Quantitative evaluation result at least includes the quantitative output of patient overall cognitive function level, daily life activity ability and neuropsychiatric symptom severity;According to quantitative evaluation result, match reasoning is carried out in combination with preset AD diagnosis and treatment specification and evidence-based medicine knowledge base, and personalized health management decision report is generated;Health management decision report includes at least one of cognitive intervention suggestion, non-drug therapy scheme, care guide points and disease risk early warning.

Exemplary light control devices and methods provide a regional variation of visual information and sampling (“V-VIS”) of an ocular field of view that improves or stabilizes vision, ameliorates a visual symptom, reduces the rate of vision loss, or reduces the progression of an ophthalmic or neurologic condition, disease, injury or disorder. The V-VIS devices and methods generate a moving aperture effect anterior to a retina that samples and delivers to the retina environmental light from an ocular field of view at a sampling rate between 50 hertz and 50 kilohertz. Certain of these V-VIS devices and methods may be combined with augmented or virtual reality, vision measurement, vision monitoring, or other therapies including, but not limited to, pharmacological, gene, retinal replacement and stem cell therapies.

The present invention relates to a method for determining or predicting the response of a patient diagnosed with melanoma to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with melanoma to specific medicaments. More specifically, the present invention provides methods which measure kinase and / or phosphatase activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in samples, preferably blood samples, of said patients.

The invention discloses a yang-warming and kidney-tonifying paste patch for preventing diabetes from being converted into diabetic kidney and a preparation method thereof. The traditional Chinese medicine ointment patch is prepared from traditional Chinese medicines such as radix rehmanniae preparata, fructus evodiae, clove, cortex cinnamomi, radix codonopsis, radix puerariae and semen cuscutae, and is prepared by grinding the traditional Chinese medicines into powder, blending the powder into paste and preparing the paste into a cylindrical medicine cake. The traditional Chinese medicine composition acts on the Shenshu acupoint through acupoint application, and traditional Chinese medicine ingredients are used for regulating kidney qi and blood and protecting kidney functions. Clinical tests show that a test group using the application is remarkably superior to a control group in the aspect of improving the traditional Chinese medicine syndromes. The fatty acid binding protein 1 in the early kidney injury marker urine has the effects of regulating lipid metabolism and resisting oxidative stress, can protect renal tubule cells, and has the early kidney injury warning capability, and a test group applying the application has a remarkable effect of reducing the level of the fatty acid binding protein 1. Safety analysis shows that the application is low in adverse reaction occurrence rate and good in safety. The invention provides a traditional Chinese medicine non-drug therapy which has no gastrointestinal burden and is convenient for long-term persistence for preventing and treating the diabetic kidney disease.

To provide an expandable multi-excipient structured dosage form for extended drug release.SOLUTION: Many drug therapies can be greatly improved by dosage forms that reside in the stomach for an extended period of time and release the drug slowly. Accordingly, disclosed herein is an expandable structured dosage form for extended release. Dosage forms generally comprise a three dimensional structural framework of thin, solid elements. The elements comprise at least one drug, at least one physiological fluid-absorbing excipient, and at least one strength-enhancing excipient. Upon ingestion, the three dimensional structural framework expands in at least one dimension to form an expanded semi-solid mass that can be retained in the stomach for an extended period of time and release the drug.SELECTED DRAWING: Figure 2

Cannabinoids and terpenoids, which are non-psychoactive elements found in stressed plants, are being studied as possible supplemental treatments for symptoms of drug withdrawal related to remodeling. The therapeutic properties, in addition to reducing cue-induced drug cravings, are very relevant to opioid, cocaine, or cannabis withdrawal syndromes and should be included in standard detoxification programs to mitigate the symptoms of drug withdrawal. Since there is no way to stop this addiction without suffering from serious adverse effects or developing a self-addiction to pharmacological therapies, opioids, cocaine, and cannabis are extremely addictive substances. Using low-dose mixtures of terpenes, terpenoids, and cannabinoids, this innovation seeks to provide a revolutionary anti-addictive analgesic regimen that will safely and effectively cure individuals who are addicted to opioids, cannabinoids, cocaine, or self-addictive substances. Blocking the effects of addiction by inhibiting physiological metabolic processes, these compounds have safe and effective pharmacological, neurobiological, and psychological mechanisms for curing addiction.

The invention belongs to the technical field of traditional Chinese medicine compositions, and provides a traditional Chinese medicine composition, an external application and application, the traditional Chinese medicine composition comprises the following raw materials by weight: 3-4 parts of euphorbia kansui, 9-12 parts of spina gleditsiae, 6-9 parts of cherokee rose fruit, 3-5 parts of clove, and 3-5 parts of cinnamon. The invention further provides an external application which comprises the traditional Chinese medicine composition and a carrier used for promoting transdermal absorption of the traditional Chinese medicine composition and guiding the medicine to move downwards. The traditional Chinese medicine composition has the characteristics of simplicity, easiness in implementation, small side effect, wide application range, definite curative effect, high safety, integration of non-drug therapy and external treatment dimension, strong treatment complementarity and low cost.

The cough treatment device is characterized in that the cough treatment device is provided with a light source for emitting light rays and a light ray irradiation probe for irradiating the light rays, and the light rays emitted by the light source are irradiated from the light ray irradiation probe to the vagus nerve of the neck of a patient and the vicinity of the vagus nerve in a percutaneous manner; the purpose of the present invention is to provide a safe and effective therapeutic method, which has few side effects, instead of a drug therapy that causes systemic symptoms, by directly suppressing hyperfunction of vagus nerves in the vicinity of the respiratory tract, which is a cause of cough.

Pharmacological or genetic inactivation of MAGL reduces neuroinflammation and neuropathology in animal models of AD. However, global inactivation of MAGL induces functional tolerance of CB IR, which reduces the effectiveness of pharmacotherapies. Evidence has shown that selective inactivation of MAGL in astrocytes, but not in neurons, reduces neuropathology and synaptic and cognitive impairments in TBI. In particular, results showed that inactivation of astrocytic MAGL attenuates AD neuropathology and prevents deterioration in LTP, spatial learning and memory in AD animals. This shows that neuroprotective effects of global MAGL inactivation largely result from limiting 2-AG degradation in astrocytes, rather than in neurons. Therefore, selective inactivation of astrocytic MAGL provides a better therapeutic outcome for AD, as this greatly minimizes the potential adverse effects resulting from global inactivation-induced disruption of 2-AG degradation in neurons and in other peripheral tissues. To this end, an AAV-mediated gene silencing approach to knock MAGL selectively in astrocytes is presented.